LTR Pharma (ASX:LTP) executed a definitive telehealth distribution agreement with Shed Holdings, a US direct-to-consumer telehealth platform, converting a previously disclosed binding term sheet into a definitive commercial agreement for the planned US commercialization of ROXUS, according to a Friday Australian bourse filing.
The company said Shed has committed to support the delivery of not less than 150,000 ROXUS units during the first 12 months following commercial launch.
ROXUS is the company's fast-acting intranasal spray for the treatment of erectile dysfunction.
The company's shares rose 11% in recent Friday trade.